Mycotoxins vs. Motherhood: How Fungal Toxins Are Silently Disrupting Hormone Production

I. Not Just Moldy Grains—But Molecular Sabotage

We’ve all heard the warnings: don’t eat moldy bread, toss out that suspicious cornmeal, watch for spoiled feed. For decades, mycotoxins — fungal byproducts that hitchhike on food crops — have been seen primarily as toxic threats to the liver or immune system.

Dangerous, yes. But mostly in large doses, mostly in livestock, and mostly preventable.

But now, science is uncovering something far more intimate.
It turns out that mycotoxins may be quietly undermining a fundamental pillar of life: reproductive hormone production. Specifically, they’re interfering with progesterone, the hormone that sustains pregnancy, stabilizes the uterus, and protects early fetal development.

This isn’t a matter of massive contamination or acute poisoning. According to a new study, it’s happening at low, barely noticeable levels — the kind that could be present in everyday food systems.

II. The Target: Progesterone’s Unsung Gatekeeper

At the heart of this discovery lies a single enzyme: 3β-hydroxysteroid dehydrogenase type 1 (3β-HSD1).
It lives in the placenta and plays a starring role in pregnancy — converting pregnenolone into progesterone (P4), the hormone responsible for preparing and maintaining the womb.

Researchers tested seven well-known mycotoxins on this enzyme’s activity:

• Cyclopiazonic acid (CPA)
• Deoxynivalenol (DON)
• Patulin (PAT)
• Zearalenone and its metabolites (α-ZEL, β-ZEL, β-ZAL)

The results? Six out of seven significantly blocked the enzyme’s activity.

When these toxins were applied to cultured human trophoblast cells — the kind that help form the placenta — the impact was immediate and measurable:
Progesterone production dropped significantly.

Even at just 10 μM, the cells stopped making enough of the hormone needed to maintain a healthy pregnancy.

III. This Isn’t Just About Humans

Here’s where things get even more unsettling: the same inhibitory effect was seen on the rat version of the enzyme (3β-HSD4). That’s a strong sign that the mechanism is conserved across species.

If true, this means the risks extend far beyond human pregnancy:

• Livestock exposed to contaminated feed may suffer from early pregnancy loss or reduced fertility — even without visible illness.
• Wildlife in contaminated ecosystems could experience population shifts linked to subtle hormonal dysfunction.
• And across mammals, entire generations may feel the echo of endocrine interference that no one saw coming.

In short: the gatekeeper enzyme doesn’t just serve humans — and the mycotoxins don’t discriminate.

IV. The Molecular Mechanism: A Complex Kind of Interference

This isn’t a blunt-force toxin story. The mycotoxins didn’t just clog the enzyme’s active site.

Using molecular docking simulations, the researchers found that these compounds interfered with NAD+ binding regions — indicating a mixed-type inhibition.

That means they disrupt both the active function and the structural co-factors the enzyme needs to work.

In simpler terms: the sabotage is smart. And that makes it harder to predict, detect, or neutralize.

The team also used structure–activity relationship (SAR) analysis and developed 3D pharmacophore models to identify molecular patterns that predict how likely a compound is to interfere with hormone synthesis.

Features like hydrophilicity and molecular density appeared linked to inhibition strength.

These tools could be game-changers: they allow us to screen hundreds of unknown compounds — not just for carcinogenicity or acute toxicity, but for their subtle, hormone-altering potential.

V. Why This Matters Now

Let’s be clear: we are not prepared for this.

✔️ Food safety regulations may be missing the mark.
CPA, the most potent inhibitor, is rarely the focus of regulatory frameworks compared to more infamous toxins like DON or zearalenone. Yet this study suggests it may have an even greater effect on pregnancy outcomes.

✔️ Our toxicology screens are outdated.
Most current tests focus on liver damage, cancer risk, or acute toxicity. But they often ignore endocrine effects, especially subtle hormonal shifts that can affect reproduction without causing immediate illness.

✔️ Pregnancy researchers need to look again.
This isn’t about rare poisoning events. It’s about chronic, low-dose exposure — the kind that could quietly influence fertility, implantation, and gestation at a population level.

✔️ Predictive toxicology is the way forward.
With SAR and docking models, scientists could one day screen all new food-contact chemicals, mycotoxins, or pollutants for endocrine-disrupting potential — before they end up in the food chain.

VI. Closing Thought: The Silent Saboteurs

For years, we’ve treated mycotoxins like distant threats — problems of grain storage, of cattle feed, of poorly regulated markets. But what this study reveals is something far more intimate, and far more urgent.

These aren’t just contaminants.
They’re hormone hackers — molecules capable of reaching into the most sacred biological systems and flicking off the switches that sustain life.

And because the enzyme they target is shared across mammals, their impact could ripple from womb to world. From birth rates to biodiversity. From human fertility to ecological health.

This isn’t alarmism. It’s a recalibration.
A reminder that in the microbial world, danger isn’t always loud.
Sometimes, it comes in whispers — in μM concentrations, in chemical mimicry, in enzymes quietly misfiring.

The question is: Are we listening yet?

References

• Schmutzler, C. et al. (2024). Mycotoxins inhibit human placental 3β-hydroxysteroid dehydrogenase and impair progesterone synthesis. Toxicological Sciences, 197(2), 432–445. DOI: 10.1093/toxsci/kfae073
• World Health Organization (WHO): Mycotoxin Fact Sheet
• European Food Safety Authority (EFSA): Deoxynivalenol and Zearalenone Assessment Reports
• PubChem entries: Cyclopiazonic acid, Patulin, Zearalenone

Frequently Asked Questions

How do mycotoxins affect pregnant women?

Pregnancy creates multiple factors that increase both the risk and consequences of mycotoxin exposure. Altered gastrointestinal function: pregnancy changes gut motility, microbiome composition, and intestinal permeability in ways that may alter mycotoxin absorption; increased intestinal permeability (sometimes called ‘leaky gut’) during early pregnancy could increase systematic mycotoxin absorption from the same dietary exposure. Placental transfer: several mycotoxins cross the placenta and have been detected in cord blood and fetal tissue; aflatoxin B1-lysine adducts (a marker of aflatoxin exposure) have been detected in cord blood samples from West African hospitals, indicating direct fetal exposure. Fetal vulnerability: developing organs and tissues are more sensitive to many toxic insults than adult equivalents; the liver (primary site of aflatoxin metabolism and toxicity), the nervous system (fumonisin target), and the reproductive organs (zearalenone target) are all undergoing critical development during pregnancy. Immunological changes: pregnancy-associated immune tolerance changes may alter the maternal immune response to mycotoxin-induced inflammation, potentially increasing susceptibility to some effects. The epidemiological evidence: aflatoxin exposure during pregnancy in sub-Saharan Africa is associated with reduced birth weight and impaired fetal growth in multiple cohort studies; these effects have biological plausibility and consistent directionality.

What is zearalenone and why is it a concern for women?

Zearalenone (ZEN) is a non-steroidal oestrogenic mycotoxin produced by Fusarium graminearum and related species on maize, wheat, and other cereals, particularly under wet field conditions during grain fill and storage. Its oestrogenic mechanism: ZEN and its metabolites (α-zearalenol, β-zearalenol) bind the oestrogen receptor (ER) with lower affinity than endogenous oestradiol but are present at sufficient concentrations in contaminated food to exert oestrogenic biological effects in sensitive species. In livestock: ZEN’s oestrogenic effects are most clearly documented in pigs, which are exquisitely sensitive; even low ZEN dietary exposure causes prepubertal vulval swelling, uterine hypertrophy, reduced litter sizes, and reproductive disruption—these effects are economically significant for the swine industry and drive ZEN regulation in animal feed. In humans: the evidence for oestrogenic effects of ZEN in humans at typical dietary exposure is less clear; several epidemiological studies have found associations between ZEN exposure biomarkers and altered pubertal timing in girls; some studies suggest effects on menstrual cycle regularity at higher exposures. Regulatory status: EU has set maximum levels for ZEN in cereal products (0.05–0.1 mg/kg depending on product type); Tolerable Daily Intake (TDI) has been set by EFSA.

Can mycotoxins be transmitted through breast milk?

Yes—ochratoxin A (OTA), aflatoxin M1 (AFM1, the hydroxylated metabolite of aflatoxin B1), and zearalenone have all been detected in human breast milk samples in multiple studies. Aflatoxin M1 in breast milk: AFM1 is produced in the body when aflatoxin B1 is metabolised; it is excreted in milk (in cows and humans) in proportion to AFB1 dietary intake; AFM1 has approximately 2–10% of the hepatotoxic and carcinogenic potency of AFM1; human breast milk studies in West Africa, Turkey, Iran, and other regions find AFM1 in a significant proportion of samples, particularly in regions with high aflatoxin dietary exposure. OTA in breast milk: OTA has been detected in breast milk in multiple European and developing country studies; the developing infant brain and kidney are particularly sensitive to OTA’s nephrotoxic and potentially neurotoxic effects. ZEN in breast milk: ZEN and its metabolites have been detected at lower rates than OTA and AFM1. The significance for policy: current mycotoxin regulations focus on dietary exposure via solid food; the breast milk transmission pathway means infants have an additional exposure route not captured by standard dietary exposure assessments; regulatory maximum levels for mycotoxins in infant formula exist (AFM1: 0.025 μg/kg EU) but no equivalent standards for breast milk.

Do mycotoxins cause birth defects?

The relationship between mycotoxin exposure and birth defects is best established for fumonisins, with suggestive but less conclusive evidence for other mycotoxins. Fumonisins and neural tube defects: fumonisins inhibit the enzyme ceramide synthase (sphinganine N-acyltransferase), disrupting sphingolipid metabolism; sphingolipids are essential for cell signalling and membrane function during embryonic development; in animal models, fumonisin feeding during critical developmental periods produces neural tube defects (NTDs) including anencephaly and spina bifida at doses achievable through dietary exposure. Folate interaction: folate (vitamin B9) deficiency is the most established dietary cause of NTDs; fumonisin’s disruption of folate uptake mechanisms appears to amplify NTD risk when folate status is marginal—the combination of high fumonisin exposure and low folate (common in maize-dependent low-income populations) may produce synergistic NTD risk. Epidemiological evidence: ecological studies in Texas border communities and South Africa have found associations between high fumonisin exposure (estimated from corn contamination surveys) and NTD rates; cohort studies establishing individual-level fumonisin-NTD associations are methodologically challenging due to exposure measurement difficulty. Regulatory response: the US FDA has set recommended action levels for fumonisins in human corn-based foods (2 mg/kg); folate fortification of corn masa flour is also supported by the FDA partly in response to fumonisin-NTD concerns in high-corn-consumption populations.

Are current food safety limits safe for pregnant women and infants?

The adequacy of current mycotoxin regulatory limits for protecting pregnant women and infants is increasingly questioned by reproductive and developmental toxicologists, and this is an area of active regulatory re-evaluation. Basis of current limits: most mycotoxin maximum levels (MLs) and tolerable daily intakes (TDIs) are derived from adult animal studies; safety factors are applied to account for human variability and species differences; however, specific developmental toxicity endpoints are not always the most sensitive endpoint in the studies used to derive limits. Known inadequacies: for aflatoxin, current limits are often derived from hepatotoxicity and carcinogenicity endpoints in adults; developmental and reproductive toxicity at lower doses is not fully captured in current risk assessments. The EU EFSA has periodically re-evaluated mycotoxin TDIs and has acknowledged gaps in developmental toxicity data. For zearalenone, the TDI is based on reproductive and oestrogenic endpoints but the sensitivity of girls during early puberty—a critical hormonal window—may not be adequately captured in adult female animal studies. The precautionary position: the evidence supports precautionary measures for pregnant women and young children, including: consuming diverse diets to reduce dependence on any single potentially contaminated staple; prioritising mycotoxin-tested infant formula and baby foods; and in high-exposure regions, periconceptional folate supplementation to provide protection against fumonisin-related NTD risk.